Physician profile
Jacob Levitt
NPI 1568457679
$57,630.55
in general payments reported to CMS, 2019-2025
28 companies · $13K in 2025
The $13K reported for 2025 was more than what 93% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $7,831 · 2021: $3,979 · 2022: $4,285 · 2023: $3,104 · 2024: $2,901 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $7,743 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,015.00 |
| Food and Beverage | $7,742.69 |
| Education | $146.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $8,126.43 | 2019-2022 | |
| Janssen Biotech, INC. | $7,225.06 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $6,297.29 | 2020-2024 | Sotyktu |
| Pfizer INC. | $5,580.68 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $5,244.58 | 2019-2025 | |
| Leo Pharma INC. | $4,415.95 | 2020-2025 | Adbry, Anzupgo, Spevigo |
| Takeda Pharmaceuticals U.S.A., INC. | $3,990.00 | 2025 | |
| Dermavant Sciences, INC. | $3,409.96 | 2022-2024 | Vtama |
| Abbvie INC. | $3,199.00 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $3,181.60 | 2019-2025 | Siliq |
| Lilly USA, LLC | $2,861.01 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Genzyme Corporation | $765.26 | 2021-2024 | |
| Ucb, INC. | $759.84 | 2019-2025 | Bimzelx |
| Incyte Corporation | $695.79 | 2021-2025 | Opzelura |
| Leo Pharma As | $450.00 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $367.86 | 2024-2025 | Nemluvio, Aklief |
| Regeneron Healthcare Solutions, INC. | $229.90 | 2022-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $158.29 | 2023-2025 | Zoryve |
| Amgen INC. | $139.40 | 2019-2023 | Otezla |
| Astrazeneca Ab | $127.99 | 2020 | |
| Lnhc, INC | $125.00 | 2025 | Zelsuvmi |
| Astrazeneca Pharmaceuticals LP | $119.85 | 2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.15 | 2023-2024 | Spevigo |
| Sun Pharmaceutical Industries INC. | $26.09 | 2025 | |
| Sanofi-Aventis U.S. LLC | $23.48 | 2019 | |
| Organon LLC | $22.39 | 2025 | Vtama |
| Glaxosmithkline, LLC. | $22.11 | 2023 | Benlysta |
| Smith+Nephew, INC. | $11.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Levitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.